Results 11 to 20 of about 26,259 (260)

The making of bispecific antibodies [PDF]

MAbs, 2017
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG ...
Roland Kontermann, Ulrich Brinkmann
exaly   +3 more sources

Advances of bispecific antibodies using/application in dermatology: a review [PDF]

Frontiers in Allergy
Bispecific antibodies represent an important innovation in the field of biomedicine in recent years. Compared to monoclonal antibodies, their specific structure enables a single antibody molecule to bind to two different antigens simultaneously.
Ting Zhang, Yang Liu, Pei Xiong Liew, Yu Zhang, Zuotao Zhao   +4 more
doaj   +2 more sources

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions

Frontiers in Immunology
Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies.
Xinlin Liu, Liu Xinlin
exaly   +3 more sources

Production of native bispecific antibodies in rabbits. [PDF]

PLoS ONE, 2010
BACKGROUND: A natural bispecific antibody, which can be produced by exchanging Fab arms of two IgG4 molecules, was first described in allergic patients receiving therapeutic injections with two distinct allergens.
Wei Wang, Ruihuan Xu, Jinming Li
doaj   +1 more source

Identification of natural bispecific antibodies against cyclic citrullinated peptide and immunoglobulin G in rheumatoid arthritis. [PDF]

PLoS ONE, 2011
BACKGROUND: Previous studies indicate that natural bispecific antibodies can be readily produced in vivo when the body is simultaneously stimulated with 2 distinct antigens.
Wei Wang, Jinming Li
doaj   +1 more source

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

mAbs, 2021
Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with ...
Marlena Surowka, Wolfgang Schaefer, Christian Klein   +2 more
doaj   +1 more source

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. [PDF]

PLoS ONE, 2018
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression.
Yumei Li, Changhua Zhou, Jing Li, Jiayu Liu, Limin Lin, Li Li, Donglin Cao, Qing Li, Zhong Wang   +8 more
doaj   +1 more source

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

Frontiers in Immunology, 2023
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Laurent Gros, Nelly Pirot, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge, Thierry Chardès, Thierry Chardès, Thierry Chardès   +24 more
doaj   +1 more source

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +6 more sources

Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis

Fluids and Barriers of the CNS, 2022
Background Treatment with amyloid-β (Aβ) targeting antibodies is a promising approach to remove Aβ brain pathology in Alzheimer's disease (AD) and possibly even slow down or stop progression of the disease.
Ulrika Julku, Mengfei Xiong, Elin Wik, Sahar Roshanbin, Dag Sehlin, Stina Syvänen   +5 more
doaj   +1 more source